CoChat

Transient metabolic improvement in obese mice treated with navitoclax or dasatinib/quercetin

Open access
Sierra-Ramirez, Arantzazu, López-Aceituno, José Luis, Costa-Machado, Luis Filipe, Plaza, Adrián, Barradas, Marta, Fernandez-Marcos, Pablo Jose · 2020 · Aging
Cited by 47

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Senescent cells accumulate with obesity in the white adipose tissue of mice and humans.These senescent cells enhance the pro-inflammatory environment that, with time, contributes to the onset of glucose intolerance and type 2 diabetes.Glucose intolerance in mouse models of obesity has been successfully reversed by the elimination of senescent cells with the senolytic compounds navitoclax or the combination of dasatinib and quercetin (D/Q).In this work, we generated obese mice by high-fat diet feeding, and treated them with five consecutive cycles of navitoclax or D/Q during 16 weeks.We observed an efficient reduction in the white adipose tissue of the senescence markers senescence-associated β-galactosidase activity, Cdkn2a-p16 and Cdkn2a-p19 at the end of the 5 cycles.Mice treated with both navitoclax and D/Q showed an improvement of their insulin sensitivity and glucose tolerance during a short period of time (cycles 3 and 4), that disappeared at the fifth cycle.Also, these mice tended to increase the expression at their adipose tissue of the adipogenic genes Pparg and, Cebpa, as well as their plasma adiponectin levels.Together, our work shows that two different senolytic treatments, acting through independent pathways, are transiently effective in the treatment of obesity-induced metabolic disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/aging.103607

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 17

  1. Qi, 2012, Mechanisms of inflammatory responses in obese adipose tissue., Annu Rev Nutr, 3, 261, 10.1146/annurev-nutr-071811-150623 · DOI · Paper page
  2. Komuro, 2009, A crucial role for adipose tissue p53 in the regulation of insulin resistance., Nat Med, 1, 1082, 10.1038/nm.2014 · DOI · Paper page
  3. Bonner-Weir, 2019, Acceleration of β cell aging determines diabetes and senolysis improves disease outcomes., Cell Metab, 3, 129, 10.1016/j.cmet.2019.05.006 · DOI · Paper page
  4. Moorhead, 1961, The serial cultivation of human diploid cell strains., Exp Cell Res, 2, 585, 10.1016/0014-4827(61)90192-6 · DOI · Paper page
  5. Demaria, 2018, Hallmarks of cellular senescence., Trends Cell Biol, 2, 436, 10.1016/j.tcb.2018.02.001 · DOI · Paper page
  6. Pereira-Smith, 1995, A biomarker that identifies senescent human cells in culture and in aging skin in vivo., Proc Natl Acad Sci USA, 9, 9363, 10.1073/pnas.92.20.9363 · DOI · Paper page
  7. Campisi, 2010, The senescence-associated secretory phenotype: the dark side of tumor suppression., Annu Rev Pathol, 5, 99, 10.1146/annurev-pathol-121808-102144 · DOI · Paper page
  8. Zhang, 2019, Emerging senolytic agents derived from natural products., Mech Ageing Dev, 18, 1, 10.1016/j.mad.2019.05.001 · DOI · Paper page
  9. Muñoz-Espín, 2019, Targeting senescent cells in translational medicine., EMBO Mol Med, 1, e10234, 10.15252/emmm.201810234 · DOI · Paper page
  10. Elmore, 2006, The Bcl-2 Family Inhibitor ABT-263 Shows Significant but Reversible Thrombocytopenia in Mice., Blood, 10, 1107, 10.1182/blood.V108.11.825.825 · doi:10.1182/blood.v108.11.825.825
  11. Xiong, 2014, Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia., Cancer Chemother Pharmacol, 7, 593, 10.1007/s00280-014-2530-9 · DOI · Paper page
  12. Horio, 2006, Serum adiponectin concentration: its correlation with diabetes-related traits and quantitative trait loci analysis in mouse SMXA recombinant inbred strains., Biosci Biotechnol Biochem, 7, 677, 10.1271/bbb.70.677 · DOI
  13. Bustanji, 2015, Adiponectin serum levels correlate with insulin resistance in type 2 diabetic patients., Saudi Pharm J, 2, 250, 10.1016/j.jsps.2014.11.011 · DOI
  14. Kirkland, 2007, Aging results in paradoxical susceptibility of fat cell progenitors to lipotoxicity., Am J Physiol Endocrinol Metab, 29, E1041, 10.1152/ajpendo.00557.2006 · DOI · Paper page
  15. Faragher, 2018, Obesity and type-2 diabetes as inducers of premature cellular senescence and ageing., Biogerontology, 1, 447, 10.1007/s10522-018-9763-7 · DOI · Paper page
  16. Farmer, 1999, Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARgamma and C/EBPalpha., J Biol Chem, 27, 7946, 10.1074/jbc.274.12.7946 · DOI · Paper page
  17. Spiegelman, 1999, Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity., Mol Cell, 3, 151, 10.1016/s1097-2765(00)80306-8 · DOI · Paper page

Cited by

See all 47

Metadata

Authors
Sierra-Ramirez, A., López-Aceituno, J. L., Costa-Machado, L. F., Plaza, A., Barradas, M., & Fernandez-Marcos, P. J.
Venue
Aging
Published
2020-06-25
Volume
12
Issue
12
Pages
11337-11348
ISSN
1945-4589 (ISSN-L)
OpenAlex
W3037268978
Cited by
47
References
23
FWCI
3.39
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.